Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI
Imricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with GE HealthCare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005630/en/
Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI
Under the terms of the MOU, GE HealthCare and Imricor intend to collaborate to interface Imricor’s Advantage-MR EP Recorder/Stimulator and Northstar-MR 3D Mapping System with GE HealthCare MRI scanners. A successful collaboration will enable cardiac electrophysiology (EP) ablation procedures guided by real-time MRI, using Imricor’s catheters and other disposable devices, to be performed on the GE HealthCare MRI platform. The collaboration with GE HealthCare would expand Imricor’s potential to interface with GE HealthCare’s new and currently installed MRI scanners.
Imricor’s short-term goal is to allow sites with GE HealthCare MRI systems to participate in the upcoming “Vision-MR Ablation of Atrial FLutter” or VISABL-AFL clinical trial in the US and “Vision-MR Ablation of Ventricular Tachycardia” or VISABL-VT clinical trial in Europe. The Company’s overall goal is to broaden in the choices physicians and hospitals have when choosing an MRI platform for their iCMR labs.
“Imricor’s innovative technology has the potential to bring significant benefit to a large number of cardiac arrhythmia patients,” said Anja Brau, PhD, General Manager, GE HealthCare MR Clinical Solutions and Research Collaborations. “GE HealthCare has a long-standing history of applying MR to therapy guidance and control; we would be pleased to add Imricor’s capabilities to provide our customers with more options to treat their patients.”
“We are thrilled at the prospect of expanding the portfolio of MRI scanners that support Advantage-MR and Northstar-MR technology,” said Steve Wedan, Imricor’s CEO and Chair. “The addition of GE HealthCare will give physicians and hospitals significantly more flexibility to use the MRI hardware of their choice, when providing real-time iCMR ablations for their patients. We are grateful to our existing customers who have embraced our real-time iCMR ablation technology, and look forward to making the benefits of this technology even more widely available.”
About Imricor
Please visit http://imricor.com/investors/about-imricor/ for more information about Imricor, Foreign Ownership Restrictions, and Forward-Looking Statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005630/en/
Contact information
Nick Twohy
Vice President of Marketing, Imricor
Email: nick.twohy@imricor.com
Phone: +1 952 818 8407
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estée Lauder Announces Actress Daisy Edgar-Jones as Newest Global Brand Ambassador8.1.2026 15:00:00 EET | Press release
Estée Lauder today announced that it has signed acclaimed British actress, Daisy Edgar-Jones, as its newest Global Brand Ambassador. Daisy will represent Estée Lauder skin care, makeup, and fragrance, with her first campaign debuting on February 2nd across print, digital and in-store. She joins Estée Lauder’s current roster of global talent including Ana de Armas, Bianca Brandolini, Carolyn Murphy, Imaan Hammam, IU, Karlie Kloss, Paulina Porizkova and Yang Mi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108459289/en/ Daisy Edgar-Jones for Estée Lauder “As an actress, I love how makeup can tell a story of who we are. I have always admired how Estée Lauder celebrates confidence and individuality in women. The legacy, elegance, and strength of the brand is so inspiring,” said Daisy Edgar-Jones. “It feels surreal to be part of the Estée Lauder family – and it truly feels like a family.” “Daisy is very much the breakout sta
Kinaxis Appoints Razat Gaurav as New CEO8.1.2026 15:00:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced the appointment of Razat Gaurav as Chief Executive Officer (CEO) effective January 12, 2026, his official start date, at which time he will also join the Kinaxis Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108330975/en/ Razat Gaurav, Kinaxis CEO “After a rigorous search, the Board selected Razat to lead the company as CEO,” said Bob Courteau, Interim CEO and Board Chair at Kinaxis. “Razat’s twenty-five years of experience in supply chain solutions, his proven track record in advancing innovation-driven growth, and his passion for developing high-performing cultures make him uniquely qualified for this role. The Board looks forward to supporting Razat as he leads Kinaxis to the next phase of growth and success.” Gaurav has an established track record of building and scaling global organizations in high-growth mark
Liberty Latin America Expands Exclusive International Voice Managed Services Partnership with BTS to 22 Additional Caribbean Markets8.1.2026 14:30:00 EET | Press release
BTS, the leading provider, technology enabler, and trusted partner to CommTech players worldwide, has been appointed by Liberty Latin America (LLA) as the exclusive provider of International Voice Managed Services for 22 additional Caribbean markets. This expansion builds on the successful 2023 partnership, in which BTS was selected as the exclusive international voice provider for Costa Rica, Panama, Puerto Rico, and the U.S. Virgin Islands. With this agreement, BTS will now support International Long Distance (ILD) services across a total of 26 LLA markets. Effective January 1, 2026, BTS began handling ILD voice services for the newly added Caribbean markets, enabling greater service consistency, enhanced quality, and improved operational efficiency across LLA’s regional footprint. The 22 new markets incorporated under the expanded partnership include: Anguilla, Antigua, Bahamas, Barbados, Bonaire, British Virgin Islands, Cayman, Curaçao, Dominica, Grenada, Jamaica, Montserrat, Saba,
Det-Tronics Acquires Optronics8.1.2026 14:28:00 EET | Press release
Det-Tronics, a global leader in fire and gas safety systems, has acquired Optronics, a Norway-based company that specializes in optical gas detection technologies. Det-Tronics is part of Spectrum Safety Solutions that is based in Stamford, CT. Optronics, founded in 2018, is a technology leader in high-end optical gas detection products and solutions for energy, marine and industrial applications. Optronics has a strong record of innovation, bringing leading products and expert solutions to market for its customers. (www.optronics-technology.com) “Det-Tronics’ strategy is built on growth, innovation and quality. Optronics and Det-Tronics are a perfect fit to grow our businesses, drive new innovations and lead the market with high quality and reliable products and solutions,” noted Johannes Mario Kahlert, President of Det-Tronics. “We are very excited for the path ahead to deliver outstanding value to our customers together.” “Optronics is an innovation leader in high-end optical gas det
Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease8.1.2026 14:00:00 EET | Press release
Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced positive topline data from the Company’s Phase 1 trial of its lead asset V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumococcal disease caused by Streptococcus pneumoniae (Spn) infections. The study evaluated safety and immunogenicity in healthy volunteers, with data demonstrating an excellent safety profile and robust immune responses across all three target antigens in the vaccine. Results support further development of V-212 independently and in combination with an approved PCV. “With the significant need for an effective serotype-independent vaccine, we are pleased to report positive results, which highlight the excellent safety profile and immunogenicity of V-212 and, more broadly, validate our Synthetic Virus-Like Particle (SVLP) platform approach for the development of broad-spectrum, self-adjuvanted vaccines with high
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom